CorMedix (NASDAQ:CRMD – Get Free Report) and Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.
Insider and Institutional Ownership
34.2% of CorMedix shares are held by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are held by institutional investors. 5.2% of CorMedix shares are held by company insiders. Comparatively, 4.4% of Regulus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for CorMedix and Regulus Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CorMedix | 0 | 0 | 5 | 0 | 3.00 |
| Regulus Therapeutics | 0 | 1 | 5 | 0 | 2.83 |
Profitability
This table compares CorMedix and Regulus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CorMedix | N/A | -79.21% | -64.68% |
| Regulus Therapeutics | N/A | -55.03% | -50.15% |
Volatility & Risk
CorMedix has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
Earnings & Valuation
This table compares CorMedix and Regulus Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CorMedix | $12.26 million | 57.75 | -$46.34 million | ($0.81) | -14.41 |
| Regulus Therapeutics | N/A | N/A | -$30.04 million | ($1.07) | -1.46 |
Regulus Therapeutics has lower revenue, but higher earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Regulus Therapeutics beats CorMedix on 7 of the 11 factors compared between the two stocks.
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
About Regulus Therapeutics
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
